Credit Suisse Downgrades Maravai LifeSciences to Neutral, Lowers Price Target to $14
Portfolio Pulse from richadhand@benzinga.com
Credit Suisse analyst Dan Leonard downgraded Maravai LifeSciences (NASDAQ:MRVI) from Outperform to Neutral and lowered the price target from $18 to $14.
May 23, 2023 | 10:53 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Maravai LifeSciences downgraded to Neutral by Credit Suisse, with a lowered price target of $14.
The downgrade from Outperform to Neutral by Credit Suisse analyst Dan Leonard indicates a less optimistic outlook for Maravai LifeSciences. The lowered price target from $18 to $14 suggests a reduced potential upside for the stock, which may negatively impact its short-term price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100